Lv46
410 积分 2025-04-02 加入
Myeloid sarcoma of the breast as a first manifestation of acute myeloid leukemia: A case report
11天前
已关闭
ABCL-006 Azacytidine plus rituximab–gemcitabine–oxaliplatin as salvage treatment in patients with relapsed/refractory diffuse large B-cell lymphoma
28天前
已完结
Preliminary results of a phase II study of rituximab (R), gemcitabine (Gem), oxaliplatin (Ox) plus enzastaurin (ENZ) followed by ENZ maintenance as salvage regimen for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
1个月前
已关闭
R-GemOx Plus Nivolumab Vs R-GemOx As Second-Line Therapy for Large B-Cell Lymphoma in Transplant-Ineligible Patients: Interim Analysis of the Niveau Trial, an International, Randomized Phase 3 Study of the AGMT, GLA, HOVON, Lysa and PLRG
1个月前
已完结
PB2144: PEARL: A STUDY TO ASSESS THE EFFICACY AND SAFETY OF PENPULIMAB PLUS LENALIDOMIDE, RITUXIMAB, GEMCITABINE AND OXALIPLATIN IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA
1个月前
已完结
Dual epigenetic agents plus rituximab–gemcitabine–oxaliplatin as salvage treatment in relapsed/refractory diffuse large B‐cell lymphoma patients failure of salvage chemotherapy
1个月前
已完结
P1189: INITIAL SAFETY RUN-IN RESULTS OF THE PHASE III POLARGO TRIAL: POLATUZUMAB VEDOTIN PLUS RITUXIMAB, GEMCITABINE, AND OXALIPLATIN IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
1个月前
已完结
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 11. bis 14. Oktober 2024, Basel
1个月前
已关闭
Initial safety run-in results of the phase III POLARGO trial: Polatuzumab vedotin plus rituximab, gemcitabine, and oxaliplatin in patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL)
1个月前
已关闭
Abstract Book: 25th Congress of the European Hematology Association Virtual Edition, 2020
1个月前
已完结
皖公网安备34019202002308
